{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"second_quarter\", filing_year = 2024 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[3183532, "163f69aa-478a-4b01-a55b-dcf0ce95f3cc", "2T", "PORT SIDE STRATEGIES, LLC", 401105394, "NEW VENTURE FUND", 2024, "second_quarter", "PHA", "H.R.4895 - Lowering Drug Costs for American Families Act - in support. Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, null, 0, 1, "2024-05-16T21:31:12-04:00"], [3183995, "67c7eca6-a703-42e3-98f0-bdcedc373954", "2T", "BLUESTONE STRATEGIES, LLC", 400658980, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2024, "second_quarter", "PHA", "Pharmacy contracting issues related to drug pricing and pharmacy networks. HR 5378, The Lower Costs More Transparency Act S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers. S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 1, "2024-06-04T14:23:35-04:00"], [3184564, "b802b3d8-9f3a-4bb5-afb8-188872da3d83", "Q2", "KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS)", 401105192, "CVS HEALTH", 2024, "second_quarter", "PHA", "Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-06-28T09:00:35-04:00"], [3184595, "41524d12-e254-4b70-8c57-b7395a237cec", "2T", "4C COMMUNICATIONS, INC.", 323717, "HEALTHCARE LEADERSHIP COUNCIL", 2024, "second_quarter", "PHA", "H.R. 7050, Substance Use Disorder Workforce Act H.R. 7312, Electronic Prescribing for Controlled Substances 2.0 Act S. 2666, Electronic Prescribing for Controlled Substances Act", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 1, "2024-06-28T14:13:37-04:00"], [3184707, "10b4230a-7780-45a3-a213-b648de6e36a7", "Q2", "PENN AVENUE PARTNERS", 400918672, "UNITEDHEALTH GROUP, INC.", 2024, "second_quarter", "PHA", "Pharmacy benefit related issues.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office", 90000, null, 0, 0, "2024-07-01T05:19:49-04:00"], [3184714, "10dd0ad2-9cf1-4550-a762-9871f3a675e6", "Q2", "PENN AVENUE PARTNERS", 400918672, "ALKERMES, INC.", 2024, "second_quarter", "PHA", "Regulatory and legislative issues impacting Alkermes. Appropriations.", "HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office", 50000, null, 0, 0, "2024-07-01T05:24:45-04:00"], [3184886, "67e8a608-5a36-4b84-abd7-bb73dee5d2c4", "Q2", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2024, "second_quarter", "PHA", "Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.", "HOUSE OF REPRESENTATIVES,SENATE", null, 144981, 0, 0, "2024-07-01T10:54:57-04:00"], [3185074, "d155dca3-4598-46a2-8611-2a3831d1dea9", "Q2", "REPUBLIC CONSULTING, LLC", 401016871, "IQVIA", 2024, "second_quarter", "PHA", "Monitor Health Data Policy.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-01T14:44:07-04:00"], [3185159, "438d4de9-ed81-4804-8a09-6f8a4ff0cb99", "Q2", "E3 STRATEGIC CONSULTING GROUP", 401104104, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2024, "second_quarter", "PHA", "Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act\"); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act; HR 6283 - The Drug Act; HR 5378 - Lower Costs, More Transparency Act.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-01T16:18:13-04:00"], [3185177, "c92e1559-ea3d-4943-8276-69ec7c00573d", "Q2", "FROST BROWN TODD LLC", 283572, "DISPOSERX", 2024, "second_quarter", "PHA", "Support Act, SIPPI Act", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-01T16:39:58-04:00"], [3185658, "596b20c2-f147-4dc0-a8cb-fa185ca009fc", "Q2", "CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER", 312496, "CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER", 2024, "second_quarter", "PHA", "340B, Hospital at Home", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", null, 34865, 0, 0, "2024-07-03T08:15:00-04:00"], [3185923, "0bc1b8ce-c413-4098-b2da-ae3e2a507609", "Q2", "DAVE KOLBE CONSULTING", 401104329, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2024, "second_quarter", "PHA", "H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-03T17:00:20-04:00"], [3186031, "1acc68e7-41b5-4ccb-b9c7-8f3cf312f009", "Q2", "WAKEFERN FOOD CORP.", 400588798, "WAKEFERN FOOD CORP.", 2024, "second_quarter", "PHA", "Comprehensive pharmacy benefit manager (PBM)/DIR fee reform H.R. 5378 - \"Lower Costs, More Transparency Act\" S. 3430 - \"Better Mental Health Care, Lower-Cost Drugs, and Extenders Act\" S. 2973 - \"Modernizing and Ensuring PBM Accountability Act\" Legislative measures add more transparency", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2024-07-05T10:52:01-04:00"], [3186237, "a27ff12b-c229-4ffb-b10a-5516920242ac", "Q2", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2024, "second_quarter", "PHA", "H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation. H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large. H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications. S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees. S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients. H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE", 70000, null, 0, 0, "2024-07-06T09:12:24-04:00"], [3186429, "955f240a-8b40-4fb6-93f4-35ec7ef199aa", "Q2", "MASON STREET CONSULTING, LLC", 401105150, "CAPITAL RX INC.", 2024, "second_quarter", "PHA", "PBM Reform.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-07T08:58:05-04:00"], [3186503, "d765aa46-9c82-4922-8581-f4b0faf733d8", "Q2", "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 26672, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2024, "second_quarter", "PHA", "Lower healthcare costs and bring transparency to pharmacy benefit managers (PBMs) through meaningful PBM reforms. H.R. 1613 Drug Price Transparency in Medicaid Act H.R. 1770 Equitable Community Access to Pharmacist Services Act H.R. 2534 Protect 340B Act of 2023 H.R. 2816 The PBM Sunshine and Accountability Act H.R. 2880 Protecting Patients Against PBM Abuses Act H.R. 2882 Fiscal 2024 Further Consolidated Appropriations Act (3-22 package) H.R. 3561 The Patient Act H.R. 4366 Consolidated Appropriations Act, 2024 (3-8 package H.R. 5378 Lower Costs, More Transparency Act H.R. 5385 The Medicare PBM Accountability H.R. 5393 To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes. H.R. 5400 TheNeighborhood Options for Patients Buying Medicines (NO PBMs) Act H.R. 7623 Telehealth Modernization Act of 2024 H.R. 7635 The 340B Patients Act of 2024 H.R. 8574 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act S. 1038Drug Price Transparency in Medicaid Act S. 113Prescription Pricing for the People Act S. 127Pharmacy Benefit Manager Transparency Act S. 1339Pharmacy Benefit Manager Reform Act S. 1491Pharmacy and Medically Underserved Areas Enhancement Act S. 2052Protect Patient Access to Pharmacies Act S. 2436TheNeighborhood Options for Patients Buying Medicines (NO PBMs) Act S. 2477Equitable Community Access to Pharmacist Services Act S. 2666ECAPS 2.0 Act S. 2973Modernizing and Ensuring PBM Accountability Act (MEPA) S. 3393The SUPPORT Act S. 3430Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 (Better Act)", "HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,White House Office", null, 1800000, 0, 0, "2024-07-08T08:35:53-04:00"], [3186869, "dc734910-e23d-4f7f-9f62-22ebc8b021db", "Q2", "DENTONS US LLP", 36105, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA", 2024, "second_quarter", "PHA", "Federal issues impacting workforce and innovation in the pharmaceutical industry.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-08T16:28:01-04:00"], [3186986, "3b91469e-53cc-48af-82f6-526569725807", "Q2", "THE MAJORITY GROUP, LLC", 400713141, "SHARX, LLC", 2024, "second_quarter", "PHA", "Advocate on behalf of SHARx with Congress and relevant agencies on solutions involving the high costs of prescription medications.", "HOUSE OF REPRESENTATIVES,SENATE", 65000, null, 0, 0, "2024-07-09T09:23:32-04:00"], [3187065, "3799165c-8552-43ed-b5b5-702ef0675195", "Q2", "MCDERMOTT+ LLC", 401103287, "ALLIANCE FOR RURAL HOSPITAL ACCESS", 2024, "second_quarter", "PHA", "Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2024-07-09T11:20:07-04:00"], [3187284, "4c83a7ca-94f0-4864-9393-444c254f875b", "Q2", "RAY ANDERSON", 401105487, "340B HEALTH", 2024, "second_quarter", "PHA", "Contract Pharmacy-HR 7635, The 340B PATIENTS Act of 2024 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program)", "HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2024-07-09T13:53:05-04:00"], [3187795, "ed41b364-9371-4e3a-9f92-be72866b86c5", "Q2", "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 401103605, "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 2024, "second_quarter", "PHA", "Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains", "HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2024-07-10T11:16:42-04:00"], [3188059, "6cb41732-f98c-4ac9-948f-699318899057", "Q2", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2024, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-10T14:48:35-04:00"], [3188078, "8795b422-2834-492d-9f1e-ff37f74673cf", "Q2", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2024, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-10T14:56:26-04:00"], [3188103, "0633190e-d2b6-47c5-a1cb-29f3390359a8", "Q2", "MARSHALL & POPP, LLC", 401105121, "PFIZER, INC.", 2024, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-10T15:02:40-04:00"], [3188130, "aeda8ec8-bbb9-4894-a49e-306d7403e3f2", "Q2", "MARSHALL & POPP, LLC", 401105121, "SANOFI U.S. SERVICES, INC.", 2024, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. Issues related to Type 1 diabetes screening.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-10T15:17:31-04:00"], [3188484, "35a72f5b-c0ec-4c2e-9ed3-7a103599223e", "Q2", "MR. H.R. BERT PENA", 400323519, "MARGO RX LLC(DBA RICHARD'S PHARMACY)", 2024, "second_quarter", "PHA", "PBM AND DRUG PRICES", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2024-07-11T10:19:32-04:00"], [3188759, "bb9efb6d-24a4-4e6f-b5e8-8296f08acbc6", "Q2", "GOVERNMENT COUNSEL, LLC", 401105070, "HEALTHCARE DISTRIBUTION ALLIANCE", 2024, "second_quarter", "PHA", "Issues relating to the prevention and mitigation of pharmaceutical shortages.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-11T12:46:29-04:00"], [3188840, "6485cf90-debe-4d44-91de-6a0c88b82230", "Q2", "COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE", 11003, "COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE", 2024, "second_quarter", "PHA", "CCAGW Urges Senate Judiciary Committee to Protect IP rights in Biopharmaceutical Industry CCAGW Submits Testimony to House Energy and Commerce Committee on 340B drug discount program", "HOUSE OF REPRESENTATIVES,SENATE", null, 100000, 0, 0, "2024-07-11T13:39:30-04:00"], [3188843, "f2ccb890-7e08-46e3-b597-74878432fae9", "Q2", "LMH STRATEGIC SOLUTIONS", 401108183, "AVADEL PHARMACEUTICALS, PLC", 2024, "second_quarter", "PHA", "Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-11T13:40:51-04:00"], [3188850, "e8f8aa8a-b87a-4c5d-8ae3-2d4f8a5ad28c", "Q2", "LMH STRATEGIC SOLUTIONS", 401108183, "GLAXOSMITHKLINE LLC", 2024, "second_quarter", "PHA", "General healthcare issues impacting GSK. H.R.7085 - BIOSECURE Act. H.R.830 - HELP Copays Act. H.R.5378 - Lower Costs, More Transparency Act. S.1542 - DRUG Act.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2024-07-11T13:48:04-04:00"], [3188857, "506232f8-da19-44f6-ba24-b36b6ca4dc65", "Q2", "LMH STRATEGIC SOLUTIONS", 401108183, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2024, "second_quarter", "PHA", "Prescription drug payment reform. Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-11T13:51:02-04:00"], [3189445, "7fe96de9-2251-4fea-a7c8-b5cbfeda9457", "Q2", "FLYNN & ASSOCIATES, INC.", 15020, "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION", 2024, "second_quarter", "PHA", "Drug importation Price controls Pharmacy Benefit Manager issues HR 2880 and HR 6283", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-12T12:21:55-04:00"], [3189585, "a8ab7cd6-8753-4735-9858-63840af2c544", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)", 2024, "second_quarter", "PHA", "Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA)", "Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 80000, null, 0, 0, "2024-07-12T13:52:07-04:00"], [3189611, "e0918c5c-b2da-400e-878b-15b8bec85069", "Q2", "PUBLIC CITIZEN", 32362, "PUBLIC CITIZEN", 2024, "second_quarter", "PHA", "Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 73300, 0, 0, "2024-07-12T14:06:41-04:00"], [3190091, "d111ad3f-d63c-4f32-9f06-94b11635eb83", "Q2", "FORBES-TATE", 400976792, "PHRMA", 2024, "second_quarter", "PHA", "Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2024-07-13T01:35:32-04:00"], [3190278, "164aa69d-fb17-43c1-aafa-4a2c107769b7", "Q2", "THORSEN FRENCH ADVOCACY LLC", 400599826, "HEALTHCARE DISTRIBUTION ALLIANCE", 2024, "second_quarter", "PHA", "General issues related to opioid abuse and access to medication assisted treatment. Drug Shortages.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-13T14:29:36-04:00"], [3190294, "b8ebcc9a-8fbd-423d-a956-0eb595fc94c7", "Q2", "THORSEN FRENCH ADVOCACY LLC", 400599826, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2024, "second_quarter", "PHA", "Issues related to drug pricing. Issues realted to anti-competitive tactics in the pharmaceutical marketplace.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-13T14:43:33-04:00"], [3190780, "85346aa1-3c14-4384-bbf0-643a27df37fe", "Q2", "FORBES-TATE", 400976792, "CALIFORNIA LIFE SCIENCES ASSOCIATION", 2024, "second_quarter", "PHA", "Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2024-07-14T14:10:39-04:00"], [3190830, "7d72bd7f-041b-43b3-bc04-d9532b957b1b", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "WALGREEN CO.", 2024, "second_quarter", "PHA", "Pharmacist provider status Issues related to drug pricing Issues related to access and distribution of pharmaceutical products Issues related to HIV Testing", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-14T14:55:10-04:00"], [3191272, "86857ac8-8fe3-464d-bd2f-c07dfdc35806", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "ABBOTT LABORATORIES", 2024, "second_quarter", "PHA", "Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, the Equitable Community Access to Pharmacist Services Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-15T08:52:29-04:00"], [3191294, "bf187fcc-4caf-4b4a-b855-aaa8fb8b98f9", "Q2", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2024, "second_quarter", "PHA", "H.R. 1839/S. 993 Combating Illicit Xylazine Act, all provisions H.R. 4531 Support for Patients and Communities Reauthorization Act, Section 203 S. 3393 SUPPORT for patients and Communities Reauthorization Act, review of language related to xylazine for potential inclusion S. Amendment #1916 to H.R. 3935 FAA Reauthorization Act of 2024, updated Combating Illicit Xylazine Act language", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE", null, 340000, 0, 0, "2024-07-15T09:09:30-04:00"], [3191352, "e9c9684c-7015-4f38-a261-5e1bc7a2f6da", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "AMERICAN KRATOM ASSOCIATION", 2024, "second_quarter", "PHA", "Issues related to Food and Drug Administration regulatory and consumer access. Issues related to H.R. 5905, Federal Kratom Consumer Protection Act, and the Fiscal Year 2025 Agriculture Appropriations bills.", "HOUSE OF REPRESENTATIVES", 50000, null, 0, 0, "2024-07-15T09:53:53-04:00"], [3191373, "65a2d48e-1bfc-4b88-a0ad-b1220a9330ad", "Q2", "WAXMAN STRATEGIES", 401103693, "340B HEALTH", 2024, "second_quarter", "PHA", "Issues affecting the 340B drug pricing program; Appropriations for 340B program.", "HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2024-07-15T10:06:50-04:00"], [3191645, "ee71ce1b-400e-4f21-850f-75e959a6a3f2", "Q2", "ACADEMY OF MANAGED CARE PHARMACY", 48793, "ACADEMY OF MANAGED CARE PHARMACY", 2024, "second_quarter", "PHA", "Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid \"multiple best price\" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 240000, 0, 0, "2024-07-15T11:42:00-04:00"], [3192278, "e1a2e14a-4d96-4e01-8acc-5d6a717c8323", "Q2", "FOLEY & LARDNER LLP", 15042, "ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY", 2024, "second_quarter", "PHA", "Issues related to 340B; issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience.", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2024-07-15T14:57:59-04:00"], [3192340, "0c1d55e1-6c56-454b-abe7-03e7dc4a635d", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)", 2024, "second_quarter", "PHA", "Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-15T15:21:13-04:00"], [3192361, "088bb738-949f-416c-8089-e3df4bf6a35d", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2024, "second_quarter", "PHA", "General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. Issues related to Drug Enforcement Administration Pseudoephedrine quotas.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-15T15:33:37-04:00"], [3192406, "551293eb-1454-4f31-845e-fb140ad9f5e5", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CVS HEALTH", 2024, "second_quarter", "PHA", "Issues related to drug pricing transparency. Issues related to pharmacy benefit managers. Issues related to testing, vaccination and treatment including H.R. 1770 and S. 2477, the Equitable Community Access to Pharmacist Services Act. Issues related to pharmaceutical access and affordability.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-15T15:46:25-04:00"], [3192767, "29e25151-6bec-4fe0-b9c4-3c272b8dd755", "Q2", "2359 STRATEGIES", 401106114, "TRAVERE THERAPEUTICS", 2024, "second_quarter", "PHA", "Orphan Drug Act", "HOUSE OF REPRESENTATIVES,SENATE", 12000, null, 0, 0, "2024-07-15T17:54:19-04:00"], [3192913, "49fc9116-f8dc-44da-ad88-4c922749566b", "Q2", "PORT SIDE STRATEGIES, LLC", 401105394, "CENTER FOR HEALTH AND DEMOCRACY", 2024, "second_quarter", "PHA", "Issues related to out-of-pocket costs.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-15T20:46:20-04:00"], [3193127, "bc8c0297-1c46-497f-8c3f-95b68194987b", "Q2", "DESIMONE CONSULTING, LLC", 400931695, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)", 2024, "second_quarter", "PHA", "Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform; H.R.8574, To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to the Ensuring Pathways to Innovative Cures (EPIC) Act, H.R.7174.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-16T07:52:10-04:00"], [3193474, "c4e2514f-b359-4f36-b722-bcded121e831", "Q2", "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 29403, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2024, "second_quarter", "PHA", "OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Drug Enforcement Administration Pseudoephedrine quotas", "Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 163498, null, 0, 0, "2024-07-16T10:17:14-04:00"], [3193513, "641d7899-4fcc-4215-8232-650bb01041cd", "Q2", "CARD & ASSOCIATES, LLC", 84217, "AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY)", 2024, "second_quarter", "PHA", "Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2025 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies Monitor international trade issues", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-16T10:27:10-04:00"], [3193527, "5f842373-a0c3-46f9-84fe-5213d2e9f3cf", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "AIM IMMUNOTECH INC.", 2024, "second_quarter", "PHA", "Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-16T10:31:18-04:00"], [3193767, "5d2731d9-e044-4c3a-a35c-51a773a232ce", "Q2", "NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)", 28264, "NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)", 2024, "second_quarter", "PHA", "Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 70000, 0, 0, "2024-07-16T11:20:31-04:00"], [3193911, "59253fd4-ef11-4ec2-911f-55836450818c", "Q2", "AARP", 1694, "AARP", 2024, "second_quarter", "PHA", "No bill number. Discussed out-of-pocket caps for prescription drugs. No bill number. Discussed pharmacy benefit manager reforms. H.R. 4818, the Treat and Reduce Obesity Act. No bill number. Discussed medication safety at home. No bill number. Discussed Medicare drug price negotiation program. No bill number. Discussed Medicare Prescription Payment Plan. S.79, the Interagency Patent Coordination and Improvement Act of 2023. S.142, the Preserve Access to Affordable Generics and Biosimilars Act of 2023. S.148, the Stop STALLING Act. S.150, the Affordable Prescriptions for Patients Act of 2023. S.113, the Prescription Pricing for the People Act of 2023. H.R. 5539/ S. 3131, Optimizing Research Progress Hope and New Cures Act. H.R. 5547/ S. 476, Maintaining Investments in New Innovation Act. H.R. 3549/ S. 1703, the PACE Part D Choice Act of 2023. No bill number. Discussed generic prescription drug shortages. S.2220/ H.R. 4370, the PREVAIL Act. No bill number. Discussed US Patent and Trade Office proposed rule. H.R. 8848, Affordable and Safe Prescription Drug Importation Act of 2024.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 5170000, 0, 0, "2024-07-16T12:11:35-04:00"], [3194021, "0dd54bcf-a2d9-4ab4-9353-ff2d5c6b83ec", "Q2", "SHIONOGI INC.", 401107081, "SHIONOGI INC.", 2024, "second_quarter", "PHA", "Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355)", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 110000, 0, 0, "2024-07-16T12:48:24-04:00"], [3194067, "3dfa1e4c-d705-4acb-b4f9-d525ab74f15c", "Q2", "INDEPENDENT PHARMACY COOPERATIVE", 313098, "INDEPENDENT PHARMACY COOPERATIVE", 2024, "second_quarter", "PHA", "IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act IPC supports FDA delay of DSCSA enhanced data compliance-request for comments CMS Implementation of PY 2024 Medicare Part D drug rule-comments CMS Implementation of drug provisions of the IRA 2022-comments", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2024-07-16T13:11:49-04:00"], [3194110, "bd9b491e-946a-4cd5-9687-bbd667a06d18", "Q2", "POLSINELLI PC", 314911, "RESQ PHARMA", 2024, "second_quarter", "PHA", "FDA Regulatory Issues", "HOUSE OF REPRESENTATIVES", 40000, null, 0, 0, "2024-07-16T13:28:59-04:00"], [3194722, "548845d0-bece-4e1a-9dc7-4c128e045d0e", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "SHIONOGI INC.", 2024, "second_quarter", "PHA", "FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-16T16:12:51-04:00"], [3194792, "b088f369-911e-4fc6-ac2e-ce76ea191684", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "TONIX PHARMACEUTICALS HOLDING CORP.", 2024, "second_quarter", "PHA", "LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY25 Defense Appropriation for broad-spectrum antivirals, FY25 LHHS for long covid and cocaine overdose funding", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2024-07-16T16:30:38-04:00"], [3195139, "0476aa5c-2cd4-401e-b956-fa26c0589c8b", "Q2", "CORNERSTONE GOVERNMENT AFFAIRS, INC.", 75557, "MICHIGAN HEALTH & HOSPITAL ASSOCIATION", 2024, "second_quarter", "PHA", "Cybersecurity; Medicare outpatient reimbursement; H.R. 5378, Lower Cost, More Transparency Act; Medicaid coverage and Medicaid supplemental payments; health care workforce issues; Rural Emergency Hospital designation; cancer drug shortages; Centers for Medicare & Medicaid Services Minimum Staffing Standards for Long-Term Care Facilities proposed rule; and Medicaid Managed Care State Directed Payments. Engaged with Michigan congressional delegation offices.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-16T21:35:33-04:00"], [3195177, "2a428d81-3666-407f-a44e-fec4536b1dfc", "Q2", "FORBES-TATE", 400976792, "INDEPENDENT PHARMACY COOPERATIVE", 2024, "second_quarter", "PHA", "Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2024-07-16T22:49:10-04:00"], [3195227, "8001cf17-2591-417a-951d-eb310e253c74", "Q2", "HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA)", 28776, "HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA)", 2024, "second_quarter", "PHA", "Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA)", "Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 518503, 0, 0, "2024-07-17T08:19:43-04:00"], [3195369, "e4eb1d9c-996b-4316-ab66-b643d79e561b", "Q2", "RUBICON ADVISORS, LLC", 315091, "ASCENDIS PHARMA, INC.", 2024, "second_quarter", "PHA", "Food and Drug Administration, Orphan Drugs", "Food & Drug Administration (FDA)", 60000, null, 0, 0, "2024-07-17T09:58:18-04:00"], [3195383, "dc8fe36b-7547-4007-8b68-09eafe94f8be", "Q2", "RUBICON ADVISORS, LLC", 315091, "DR. REDDY'S LABORATORIES, LTD", 2024, "second_quarter", "PHA", "Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues", "Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 60000, null, 0, 0, "2024-07-17T10:00:16-04:00"], [3195385, "943f7490-b278-4bd4-bf51-7a7f1bb03407", "Q2", "RUBICON ADVISORS, LLC", 315091, "DYNAVAX TECHNOLOGIES", 2024, "second_quarter", "PHA", "Prescription User Fee, Biomedical Advance Research and Development Authority (BARDA)", "HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS)", 75000, null, 0, 0, "2024-07-17T10:01:25-04:00"], [3195388, "22a4f93e-2e92-4772-b78f-32430987e529", "2T", "RUBICON ADVISORS, LLC", 315091, "LANNETT COMPANY, INC", 2024, "second_quarter", "PHA", "Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)", 35000, null, 0, 1, "2024-07-17T10:03:20-04:00"], [3195691, "d6175d3d-194d-4b5a-8ddd-95593da3b94f", "Q2", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "HEMOPHILIA OF GEORGIA", 2024, "second_quarter", "PHA", "340B Drug Pricing Program", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-17T11:50:24-04:00"], [3195707, "5d2e4393-dd90-45ca-b34c-30fe52130f00", "Q2", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "TIDELANDS HEALTH", 2024, "second_quarter", "PHA", "Issues related to the 340B Drug Pricing Program", "SENATE", 40000, null, 0, 0, "2024-07-17T11:52:47-04:00"], [3195768, "3a8218eb-787f-4f33-bc96-8d29fe1e5ccf", "Q2", "NATIONAL RURAL LETTER CARRIERS' ASSOCIATION", 28526, "NATIONAL RURAL LETTER CARRIERS' ASSOCIATION", 2024, "second_quarter", "PHA", "H.R. 6283,\"DRUG Act\"- legislation that impacts Pharmacy Benefit Managers (PBMs), it could have the unintended consequences of reducing mail volume and increasing the costs/premiums of employer sponsored health programs. The NRLCA has not taken a position on this legislation. S. 1542, \"DRUG Act\"- Senate companion bill to H.R. 6283, the NRLCA has not taken a position on this bill.", "HOUSE OF REPRESENTATIVES,SENATE", null, 125000, 0, 0, "2024-07-17T12:06:09-04:00"], [3195926, "80f83d7a-ba26-4ddf-8b7b-1603e3370a53", "Q2", "ARNOLD & PORTER KAYE SCHOLER LLP", 4301, "NOVO NORDISK, INC.", 2024, "second_quarter", "PHA", "Issues related to pharmacy benefit managers and the 340B Program.", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2024-07-17T12:43:50-04:00"], [3195988, "c48a2ead-8b7d-4b19-8967-124bab1ef672", "Q2", "BL PARTNERS GROUP, LLC", 401105341, "ALBERTSONS COMPANIES, INC.", 2024, "second_quarter", "PHA", "Issues related to Anti-Trust, Food and Drug Regulation, Supply Chain, Farm to Market Programs, SNAP Programs and Pharmacy benefit Managers - no specific legislation.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-17T13:06:02-04:00"], [3196262, "74832e7e-c54c-46e8-bf80-c965428fd5d8", "Q2", "PRINTING UNITED ALLIANCE", 401105682, "PRINTING UNITED ALLIANCE", 2024, "second_quarter", "PHA", "Retention of FDA regulations mandating use of pharmaceutical information and prescriber data on paper. Support of H.R. 1173 (118th Congress): Patients Right to Know Their Medication Act.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2024-07-17T13:58:42-04:00"], [3196492, "5cfcc5eb-c63f-4e4b-9427-5f232b97cad8", "2A", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "SHIONOGI INC.", 2024, "second_quarter", "PHA", "FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-17T14:56:06-04:00"], [3196526, "3d6661b5-a616-46cb-8a6d-a6a0764b796e", "2T", "WEST FRONT STRATEGIES LLC", 401103493, "BLINK HEALTH INC.", 2024, "second_quarter", "PHA", "Monitor issues related to competition in pharmacy.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 1, "2024-07-17T15:01:20-04:00"], [3197138, "5a6bac2f-a59a-429e-9e2e-b862f7176bd1", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "LILLY USA, LLC", 2024, "second_quarter", "PHA", "Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act", null, 90000, null, 0, 0, "2024-07-17T18:08:02-04:00"], [3197790, "23881714-c5d8-48ed-9c8c-dfecaef8fe91", "Q2", "POLARIS GOVERNMENT RELATIONS, LLC", 307730, "CIGNA CORPORATION", 2024, "second_quarter", "PHA", "Drug pricing and issues facing the pharmacy benefit manager industry generally", "HOUSE OF REPRESENTATIVES,SENATE", 90000, null, 0, 0, "2024-07-18T09:39:16-04:00"], [3197861, "c9457a43-17a3-4efe-84b5-8b5a5b950ed9", "Q2", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2024, "second_quarter", "PHA", "Prescription drug pricing issues. S. 2305 - Biosimilar Red Tape Elimination Act. S. 148 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity (RARE) Act.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T09:58:12-04:00"], [3197910, "fc2628d4-246a-4a57-9710-7799c7136691", "Q2", "MEHLMAN CONSULTING, INC.", 284950, "HUMANA", 2024, "second_quarter", "PHA", "Prescription drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2024-07-18T10:04:49-04:00"], [3198222, "438f8637-7ba8-4eaf-a2ce-207f3c14e245", "Q2", "DA VINCI GROUP", 11548, "BOESEN & SNOW, LLC", 2024, "second_quarter", "PHA", "Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2024-07-18T10:50:11-04:00"], [3198266, "ac1ebc26-865b-41a9-b177-9d715982b55c", "Q2", "UNIVERSITY OF IOWA", 49191, "UNIVERSITY OF IOWA", 2024, "second_quarter", "PHA", "N/A", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2024-07-18T10:53:13-04:00"], [3198314, "5794acff-4a41-40eb-9878-963605974101", "Q2", "1607 STRATEGIES, LLC", 401105461, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION", 2024, "second_quarter", "PHA", "S. 2793, Modernizing and Ensuring PBM Accountability Act, all provisions. H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act, all provisions.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-18T11:01:21-04:00"], [3198547, "3f52596c-2f77-4d73-adef-8db0ec51ed69", "Q2", "340B HEALTH", 316434, "340B HEALTH", 2024, "second_quarter", "PHA", "The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act", "Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", null, 315115, 0, 0, "2024-07-18T11:43:56-04:00"], [3198573, "37e8284c-1bed-4022-8d63-2695d90a0781", "Q2", "PANNONE LOPES DEVEREAUX & O'GARA LLC", 401105501, "AMGEN", 2024, "second_quarter", "PHA", "Prescription drug pricing.", null, 9000, null, 0, 0, "2024-07-18T11:53:47-04:00"], [3198763, "efefc30d-aa6c-491f-80f7-83091f8b20e9", "Q2", "HB STRATEGIES", 401104718, "BAYER U.S. LLC", 2024, "second_quarter", "PHA", "Provide lobbying support of key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare and agricultural industries generally and Bayer specifically.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-18T12:30:54-04:00"], [3199213, "8c3f311f-64c3-4996-9a19-380e03256048", "Q2", "ARENTFOX SCHIFF LLP", 4208, "AMERICAN PHARMACY COOPERATIVE, INC.", 2024, "second_quarter", "PHA", "Prescription drug pricing generally Pharmacy Benefit Manager (PBM) reform generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions S. 1339 (Pharmacy Benefit Manager Reform Act), regarding Pharmacy Benefit Manager (PBM) reform S. 3430 (Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023), regarding Pharmacy Benefit Manager (PBM) reform H.R. 5378 (Lower Costs, More Transparency Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 6283 (DRUG Act), regarding Pharmacy Benefit Manager (PBM) reform", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2024-07-18T13:37:55-04:00"], [3199233, "be29ae3b-fbe7-44cc-bbce-e98250f1f9a5", "Q2", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2024, "second_quarter", "PHA", "Hospital discounts; 340B program", "HOUSE OF REPRESENTATIVES,SENATE", null, 2465000, 0, 0, "2024-07-18T13:40:10-04:00"], [3199389, "e9e9849b-e8d1-4748-a2de-c8a1f7722be4", "Q2", "FARRAGUT PARTNERS LLP", 401103938, "COMMUNITY ONCOLOGY ALLIANCE", 2024, "second_quarter", "PHA", "Issues related to pharmacy benefit managers. TACT Act", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2024-07-18T13:56:42-04:00"], [3199436, "07cb3e52-7040-47c1-8940-e3a172a24771", "Q2", "FARRAGUT PARTNERS LLP", 401103938, "ONEONCOLOGY INC.", 2024, "second_quarter", "PHA", "Issues related to pharmacy benefit managers.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T14:02:34-04:00"], [3199660, "05f85f4b-f9bc-4358-9994-0c8d665fb0aa", "Q2", "CAPITOL COUNSEL LLC", 313715, "EMD SERONO, INC.", 2024, "second_quarter", "PHA", "Issues regarding the availability and pricing of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T14:38:17-04:00"], [3199694, "b4d496a9-389a-4854-a9a7-75b1f8850d12", "Q2", "MARSHALL & POPP, LLC", 401105121, "ABBVIE INC.", 2024, "second_quarter", "PHA", "Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-18T14:42:08-04:00"], [3200202, "839d5f4c-2669-4c16-a1fb-70d8ef5780af", "Q2", "THE CONSILIO GROUP", 400374717, "PARATEK PHARMACEUTICALS", 2024, "second_quarter", "PHA", "Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use", "Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office", 36000, null, 0, 0, "2024-07-18T15:30:51-04:00"], [3200437, "d7290961-f9cb-4cfd-8112-156aa06cccb7", "Q2", "HANCE SCARBOROUGH", 17443, "ALLIANCE FOR PHARMACY COMPOUNDING", 2024, "second_quarter", "PHA", "Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T15:53:47-04:00"], [3200457, "b220f3f5-0831-427f-910e-fd6267185d9c", "2A", "HANCE SCARBOROUGH", 17443, "ALLIANCE FOR PHARMACY COMPOUNDING", 2024, "second_quarter", "PHA", "Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T15:56:57-04:00"], [3200721, "5d457f88-d852-40d0-b0f8-e72e74c449cc", "Q2", "WHITMER & WORRALL, LLC", 292892, "CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)", 2024, "second_quarter", "PHA", "Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-18T16:33:09-04:00"], [3200831, "34a06cb7-ee48-4a6b-9f84-7a59a2e86f40", "Q2", "TRUSYNERGY", 401107715, "BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.)", 2024, "second_quarter", "PHA", "Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; MCM PRV; SUPER BUGS Act", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2024-07-18T16:44:46-04:00"], [3200877, "1e68aa5d-9cbf-433d-8879-728905aba7d4", "Q2", "SUSAN B ANTHONY LIST", 400935704, "SUSAN B ANTHONY LIST", 2024, "second_quarter", "PHA", "Shield laws; H.R. 427, S. 95 Support and Value Expectant Moms and Babies Act; Chemical abortion; Support and Value Expectant Moms and Babies Act", "HOUSE OF REPRESENTATIVES,SENATE", null, 300000, 0, 0, "2024-07-18T16:47:23-04:00"], [3201006, "07a0253f-f196-44c9-817b-c84d839f7466", "Q2", "MEHLMAN CONSULTING, INC.", 284950, "WEDGEWOOD PHARMACY LLC", 2024, "second_quarter", "PHA", "Issues related to animal drug compounding. Issues related to FDA's CVM GFI #256 - Compounding Animal Drugs from Bulk Substances.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2024-07-18T16:58:39-04:00"], [3201112, "3606104e-7113-4b28-9380-5d42f0e2f9b0", "Q2", "HIGHMARK, INC.", 18238, "HIGHMARK INC", 2024, "second_quarter", "PHA", "Insulin Copay Caps, Drug Pricing, Pharmacy Benefit Manager (PBM) Reform, Generic Drug Manufacturing Senate Finance Committee PBM Reform Framework H.R. 5378 - The Lower Costs, More Transparency Act - A bill to require health care providers and insurers to disclose certain information about health care costs. It also establishes requirements for certain payment methodologies under Medicare and Medicaid and extends several public health programs. H.R. 1488/S. 954 - The Affordable Insulin Now Act -- A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 127. - The Pharmacy Benefit Manager Transparency Act - This bill generally prohibits pharmacy benefit managers (PBMs) from engaging in certain practices when managing the prescription drug benefits under a health insurance plan, including charging the plan a different amount than the PBM reimburses the pharmacy. S.1339 - The Pharmacy Benefit Manager Reform Act - A bill to provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. H.R.2679 - The Pharmacy Benefits Manager Accountability Act - A bill to amend the Public Health Service Act, the Employee Retirement Income Security Act, and the Internal Revenue Code of 1984 to increase oversight of pharmacy benefits manager services, and for other purposes. H.R. 3561 - PATIENT Act of 2023 - This bill expands hospital price transparency requirements and establishes additional reporting requirements with respect to prescription drugs and pharmacy benefit managers (PBMs). H.R. 2630/S. 652 - The Safe Step Act -- This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a group health plan or a health insurance issuer. H.R. 830/S. 1375 - The HELP Copays Act -- This bill requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. H.R. 2880 - Protecting Patients Against PBM Abuses Act -- This bill establishes requirements for Medicare pharmacy benefit managers (PBMs) with respect to remuneration, payments, and fees. Specifically, the bill restricts PBMs that are under contract with plans under the Medicare prescription drug benefit or Medicare Advantage from (1) receiving income for their services other than flat dollar amount service fees; (2) basing any service fees on the prices of covered drugs or any associated discounts, rebates, or other remuneration; (3) charging plan sponsors for ingredient costs or dispensing fees in amounts that are different than what is reimbursed to the pharmacy; or (4) reimbursing network pharmacies for less than that what is reimbursed to PBM-affiliated pharmacies.", "HOUSE OF REPRESENTATIVES,SENATE", null, 170000, 0, 0, "2024-07-18T17:05:02-04:00"]], "truncated": false, "filtered_table_rows_count": 294, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "second_quarter", "p1": "2024", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 294, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA", "results": [{"value": 2024, "label": 2024, "count": 294, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA", "results": [{"value": "second_quarter", "label": "second_quarter", "count": 294, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2024&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "filing_type", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA&_facet=filing_type"}, {"name": "income_amount", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA&_facet=income_amount"}, {"name": "is_termination", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA&_facet=is_termination"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA&_facet_date=received_date"}], "next": "2024,3201112", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2024&issue_code=PHA&_next=2024%2C3201112&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 2694.067901931703, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}